Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CASI Pharmaceuticals FY2023 GAAP EPS $(2.02) Misses $(1.93) Estimate, Sales $33.88M Miss $36.42M Estimate

Author: Benzinga Newsdesk | March 28, 2024 07:29am
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(2.02) per share which missed the analyst consensus estimate of $(1.93) by 4.66 percent. This is a 32.89 percent increase over losses of $(3.01) per share from the same period last year. The company reported quarterly sales of $33.88 million which missed the analyst consensus estimate of $36.42 million by 6.97 percent. This is a 21.41 percent decrease over sales of $43.11 million the same period last year.

Posted In: CASI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist